|
Name |
(8R,9R,10S,13S,14R,17S)-17-[(E,2S,5R)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
|
Molecular Formula | C29H46O | |
IUPAC Name* |
(8R,9R,10S,13S,14R,17S)-17-[(E,2S,5R)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
|
|
SMILES |
CC[C@@H](/C=C/[C@H](C)[C@@H]1CC[C@H]2[C@]1(CC[C@@H]3[C@@H]2CCC4=CC(=O)CC[C@@]34C)C)C(C)C
|
|
InChI |
InChI=1S/C29H46O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-9,18-21,24-27H,7,10-17H2,1-6H3/b9-8+/t20-,21-,24+,25-,26+,27+,28+,29-/m0/s1
|
|
InChIKey |
MKGZDUKUQPPHFM-HGIKXSOESA-N
|
|
Synonyms |
Stigmasta-4,22-dien-3-one; 55722-32-2
|
|
CAS | NA | |
PubChem CID | 133612144 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 410.7 | ALogp: | 8.5 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 17.1 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.401 |
Caco-2 Permeability: | -4.7 | MDCK Permeability: | 0.00002130 |
Pgp-inhibitor: | 0.969 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.825 |
30% Bioavailability (F30%): | 0.963 |
Blood-Brain-Barrier Penetration (BBB): | 0.025 | Plasma Protein Binding (PPB): | 88.71% |
Volume Distribution (VD): | 1.214 | Fu: | 0.99% |
CYP1A2-inhibitor: | 0.109 | CYP1A2-substrate: | 0.542 |
CYP2C19-inhibitor: | 0.281 | CYP2C19-substrate: | 0.948 |
CYP2C9-inhibitor: | 0.39 | CYP2C9-substrate: | 0.111 |
CYP2D6-inhibitor: | 0.131 | CYP2D6-substrate: | 0.116 |
CYP3A4-inhibitor: | 0.944 | CYP3A4-substrate: | 0.901 |
Clearance (CL): | 6.913 | Half-life (T1/2): | 0.139 |
hERG Blockers: | 0.635 | Human Hepatotoxicity (H-HT): | 0.332 |
Drug-inuced Liver Injury (DILI): | 0.772 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.665 | Maximum Recommended Daily Dose: | 0.935 |
Skin Sensitization: | 0.865 | Carcinogencity: | 0.174 |
Eye Corrosion: | 0.216 | Eye Irritation: | 0.061 |
Respiratory Toxicity: | 0.983 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001764 | 0.729 | D06XMU | 0.596 | ||||
ENC002882 | 0.729 | D07BSQ | 0.581 | ||||
ENC005239 | 0.729 | D02CJX | 0.534 | ||||
ENC001545 | 0.694 | D0W5LS | 0.528 | ||||
ENC001846 | 0.657 | D0Z1XD | 0.500 | ||||
ENC003369 | 0.657 | D0Y7LD | 0.495 | ||||
ENC002290 | 0.640 | D0G8BV | 0.470 | ||||
ENC004758 | 0.583 | D02AXG | 0.463 | ||||
ENC001558 | 0.583 | D08TEJ | 0.442 | ||||
ENC002665 | 0.552 | D00AEQ | 0.432 |